rt...I have to respectfully disagree here.
We are not testing Trobalt for epilepsy. Indeed we are using dosing data based on epilepsy as that is what the manufacturer and research says, so we infer back to that in relation to our suppositions on the Kv7 channels involved.
The fact is we are just "testing" this stuff. In a test you just look at what happens. The theories postulated will either stand up or not. With such small sample sizes as we have here, no matter what we know that results will be very tentative. Anything that happens, or does not happen is relevant. We don't have the luxury of nice big N sample and bell curve to muddle over later.
In this light, I find it highly significant that even a few people have had "results" at low doses (actually, more than a few). Either they are placebo'ing or not. We do not have a double blind, etc., etc. to find out. Personally I don't think it's placebos, or if so we have someone like
@undecided backing off and saying so.
Yes, there may be higher dose correlation with T "results", but that does not at all mean that lower dose effects
for T should be thrown out the window. They should be noted and absorbed and added to the knowledge base.
Time and more testers (especially long term T people with say 10 years or more) will tell if higher doses make any difference. At this point we just don't know, as no-one has tested Retigabine for T in a trial like this before...just with mice!
Keep an open mind. Very best, and this is
not a slap down! Zimichael